CPIX on Nasdaq
CUMBERLAND PHARMACEUTICALS INC
Price unavailable
Last updated Oct 16, 2026.
Overview
Compare with Aquestive Therapeutics, Inc., INTEGRATED BIOPHARMA INC or Xilio Therapeutics, Inc., or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
-6.3%Operating margin3
-6.4%Net margin3
17.6%Revenue growth, 20253
-11.4%Return on equity3
$4.8MFree cash flow3
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Products and services
Product - Sancuso brought in 24% of the revenue CUMBERLAND PHARMACEUTICALS INC broke down this way in fiscal 2025.
Products and services by year
| Products and services | 2024 | 2025 |
|---|---|---|
| Product - Sancuso | $9.0M | $11.9M |
| Product - Kristalose | $15.3M | $10.5M |
| Product - Vibativ | $7.2M | $9.5M |
| Product - Caldolor | $5.0M | $4.7M |
| Manufactured Product, Other | $1.3M | $4.1M |
| Product - Other | $1.3M | $4.1M |
| Product - Talicia | $0 | $3.3M |
| Product - Acetadote | $185.2K | $508.2K |
| Product - RediTrex | $90.2K | $11.4K |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue15¢$6.7M
- Research and development13¢$5.6M
- Other costs71¢$31.8M
- Interest1¢$496.0K
- Income tax0¢$40.3K
Out of $44.5M in revenue.3 The company lost money this year.
Where each dollar of operating cash went, fiscal 2025
- Capital spending2¢$97.9K
- Share buybacks5¢$263.5K
- Kept or used elsewhere93¢$4.6M
Out of $4.9M of cash from operations.3
Financial statements
Every line of the income statement in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net revenues | $44.5M | $37.9M |
| Cost of products sold | $6.7M | $6.6M |
| Selling and marketing | $19.1M | $17.0M |
| Research and development | $5.6M | $4.8M |
| General and administrative | $11.9M | $11.1M |
| Amortization and impairment | $4.0M | $4.7M |
| Total costs and expenses | $47.3M | $44.3M |
| Operating loss | -$2.8M | -$6.4M |
| Interest income | $476.7K | $334.4K |
| Other income - gain on insurance proceeds | $0 | $237.1K |
| Interest expense | -$496.0K | -$605.5K |
| Loss before income taxes | -$2.8M | -$6.5M |
| Income tax (expense) benefit | -$40.3K | $22.7K |
| Equity in loss of investee | -$13.2K | $0 |
| Net loss | -$2.9M | -$6.4M |
| Net (income) loss at subsidiary attributable to noncontrolling interests | $28.6K | -$36.1K |
| Net loss attributable to common shareholders | -$2.8M | -$6.5M |
| Basic (in USD per share) | -$0.19 | -$0.46 |
| Diluted (in USD per share) | -$0.19 | -$0.46 |
| Basic (in shares) | 14.9M shares | 14.1M shares |
| Diluted (in shares) | 14.9M shares | 14.1M shares |
Every line of the balance sheet in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $11.4M | $18.0M | |
| Accounts receivable, net | $16.9M | $11.7M | |
| Inventories, net | $6.2M | $4.0M | |
| Prepaid and other current assets | $2.4M | $2.8M | |
| Total current assets | $37.1M | $36.5M | |
| Non-current inventories | $9.3M | $11.0M | |
| Property and equipment, net | $264.7K | $277.4K | |
| Intangible assets, net | $14.0M | $18.0M | |
| Goodwill | $914.0K | $914.0K | |
| Operating lease right-of-use assets | $8.3M | $6.2M | |
| Investments | $4.0M | $0 | |
| Other assets | $3.0M | $2.8M | |
| Total assets | $76.8M | $75.6M | |
| Accounts payable | $18.6M | $13.9M | |
| Operating lease current liabilities | $467.8K | $356.5K | |
| Revolving line of credit - current | $0 | $5.1M | |
| Other investment liabilities | $5.1M | $0 | |
| Other current liabilities | $12.6M | $12.3M | |
| Total current liabilities | $36.7M | $31.6M | |
| Revolving line of credit - long term | $5.2M | $10.2M | |
| Operating lease non-current liabilities | $4.5M | $4.9M | |
| Total other long-term liabilities | $5.8M | $6.3M | |
| Total liabilities | $52.3M | $53.0M | |
| Common stock no par value; 100,000,000 shares authorized; 14,956,627 and 13,952,624 shares issued and outstanding as of December 31, 2025 and 2024, respectively | $51.7M | $46.8M | |
| Accumulated deficit | -$26.8M | -$24.0M | |
| Total shareholders equity | $24.9M | $22.9M | |
| Noncontrolling interests | -$336.1K | -$307.5K | |
| Total equity | $24.5M | $22.5M | $29.3M |
| Total liabilities and equity | $76.8M | $75.6M | |
| Common stock, par value (in dollars per share) | $0 | $0 | |
| Common stock, shares authorized (in shares) | 100.0M shares | 100.0M shares | |
| Common stock, shares issued (in shares) | 15.0M shares | 14.0M shares | |
| Common stock, shares outstanding (in shares) | 15.0M shares | 14.0M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$2.9M | -$6.4M |
| Depreciation and amortization expense | $4.1M | $4.9M |
| Amortization of operating lease right-of-use asset | $1.1M | $1.1M |
| Loss on co-commercialization investment | $13.2K | $0 |
| Disposal of assets | $0 | $2.7K |
| Stock-based compensation | $408.3K | $301.9K |
| Increase (decrease) in non-cash contingent consideration | $46.6K | -$1.5M |
| Increase in cash surrender value of life insurance policies over premiums paid | -$142.9K | -$140.0K |
| Noncash interest expense | $23.2K | $28.3K |
| Life insurance proceeds | $0 | -$237.1K |
| Accounts receivable | -$5.2M | -$1.9M |
| Inventories, net | $2.2M | $2.4M |
| Other current assets and other assets | -$231.8K | $189.1K |
| Operating lease liabilities | -$836.1K | $1.8M |
| Accounts payable and other current liabilities | $6.7M | -$991.4K |
| Other long-term liabilities | -$477.6K | -$153.8K |
| Net cash provided by (used in) operating activities | $4.9M | -$612.2K |
| Additions to property and equipment | -$97.9K | -$66.5K |
| Additions to intangible assets | -$84.4K | -$113.3K |
| Net investment in manufacturing | -$2.5M | $0 |
| Other investment | -$2.0M | $0 |
| Increase in cash surrender value of life insurance policies | -$47.0K | $0 |
| Life insurance policy proceeds received | $0 | $237.6K |
| Net cash provided by (used in) investing activities | -$4.7M | $57.8K |
| Borrowings on line of credit | $0 | $38.5M |
| Payments on line of credit | -$10.0M | -$36.0M |
| Proceeds from ATM offering, net | $5.3M | $0 |
| Payments made in connection with repurchase of common shares | -$263.5K | -$579.0K |
| Cash settlement of contingent consideration | -$1.7M | -$1.7M |
| Net cash provided by (used in) financing activities | -$6.7M | $196.9K |
| Net decrease in cash and cash equivalents | -$6.5M | -$357.4K |
| Interest | $441.7K | $569.2K |
| State income taxes | -$3.5K | $15.0K |
| Total cash paid included in measurement of lease liability | $836.1K | $863.3K |
| Change in unpaid invoices for intangible asset additions | $4.7K | $530 |
| Change in unpaid invoices for offering costs | $62 | -$69.7K |
| Lease liability obtained from right-of-use assets | $438.3K | $128.0K |
| Other investment liability | $2.0M | $0 |
Recent filings
- Sep 11, 20268-K/A
- Aug 28, 20268-K
- Aug 7, 202610-Q
- Aug 4, 20268-K
- Jul 13, 20268-K
- Jul 1, 20268-K
- Jun 25, 20268-K
- May 26, 2026DEFM14A
- May 15, 2026PREM14A
- May 8, 202610-Q
- May 5, 20268-K
- Apr 24, 20268-K
- Apr 23, 20268-K
- Apr 23, 2026DEFA14A
- Mar 20, 20264
Every filing from the last three years, summarized. The full record is on SEC EDGAR.1
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10